{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:45:59Z","timestamp":1777985159200,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00417-020-04849-8","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T06:02:33Z","timestamp":1595656953000},"page":"2639-2645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19"],"prefix":"10.1007","volume":"258","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3034-7809","authenticated-orcid":false,"given":"Lydia G.","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Devenport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1172-7865","authenticated-orcid":false,"given":"Irene M.","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-6476","authenticated-orcid":false,"given":"James S.","family":"Talks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"4849_CR1","unstructured":"National Institute for Health and Clinical Excellence (2012) Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. https:\/\/www.nice.org.uk\/guidance\/ta155. Accessed 5 May 2020"},{"key":"4849_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.survophthal.2019.02.008","volume":"64","author":"J Talks","year":"2019","unstructured":"Talks J, Daien V, Finger RP et al (2019) The use of real-world evidence for evaluating anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol 64:707\u2013719. https:\/\/doi.org\/10.1016\/j.survophthal.2019.02.008","journal-title":"Surv Ophthalmol"},{"key":"4849_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/bjophthalmol-2012-302167","volume":"96","author":"S Pushpoth","year":"2012","unstructured":"Pushpoth S, Sykakis E, Merchant K et al (2012) Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol 96:1469\u20131473. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302167","journal-title":"Br J Ophthalmol"},{"key":"4849_CR4","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/eye.2017.86","volume":"31","author":"JS Talks","year":"2017","unstructured":"Talks JS, James P, Sivaprasad S et al (2017) Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration. Eye 31:1613\u20131620. https:\/\/doi.org\/10.1038\/eye.2017.86","journal-title":"Eye"},{"key":"4849_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/dme.12593","volume":"32","author":"PH Scanlon","year":"2015","unstructured":"Scanlon PH, Loftus J, Starita C, Stratton IM (2015) The use of weighted health-related quality of life scores in people with diabetic macular oedema at baseline in a randomized clinical trial. Diabet Med 32:97\u2013101. https:\/\/doi.org\/10.1111\/dme.12593","journal-title":"Diabet Med"},{"key":"4849_CR6","unstructured":"The Royal College of Ophthalmologists (2020) Medical retinal management plans during COVID-19. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2020\/03\/Medical-Retinal-Management-Plan-during-COVID-19-UPDATED-300320-1-2.pdf. Accessed 29 Apr 2020"},{"key":"4849_CR7","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2437\u20132448. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"4849_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM et al (2013) HARBOUR study group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120:1046\u20131056. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.014","journal-title":"Ophthalmology"},{"key":"4849_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ophtha.2015.09.039","volume":"123","author":"JS Talks","year":"2016","unstructured":"Talks JS, Lotery AJ, Ghanchi F et al (2016) First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration. Ophthalmology 123:337\u2013343. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.039","journal-title":"Ophthalmology"},{"key":"4849_CR10","doi-asserted-by":"publisher","unstructured":"Chandra S, Rasheed R, Menon D, et al (2020) Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration [EPub ahead of print]. Eye 1\u20139. https:\/\/doi.org\/10.1038\/s41433-020-0851-y","DOI":"10.1038\/s41433-020-0851-y"},{"key":"4849_CR11","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM et al (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123:2376\u20132385. https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.032","journal-title":"Ophthalmology"},{"key":"4849_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Bracha P, Pollack J, Williams DF (2018) Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retin 2:1179\u20131187. https:\/\/doi.org\/10.1016\/j.oret.2018.06.004","journal-title":"Ophthalmol Retin"},{"key":"4849_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/bjophthalmol-2016-308668","volume":"101","author":"T Wecker","year":"2017","unstructured":"Wecker T, Ehlken C, B\u00fchler A et al (2017) Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 101:353\u2013359. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308668","journal-title":"Br J Ophthalmol"},{"key":"4849_CR14","doi-asserted-by":"publisher","unstructured":"Ang JL, Ah-Moye S, Kim LN et al (2020) A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion [EPub ahead of print]. Eye:1\u201327. https:\/\/doi.org\/10.1038\/s41433-020-0861-9","DOI":"10.1038\/s41433-020-0861-9"},{"key":"4849_CR15","doi-asserted-by":"publisher","unstructured":"Korobelnik J-F, Loewenstein A, Eldem B et al (2020) Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic [EPub ahead of print]. Graefe\u2019s Arch Clin Exp Ophthalmol:1\u20138. https:\/\/doi.org\/10.1007\/s00417-020-04703-x","DOI":"10.1007\/s00417-020-04703-x"},{"key":"4849_CR16","doi-asserted-by":"publisher","unstructured":"Kidd Man RE, Liang Gan AT, Fenwick EK et al (2020) Using uniocular visual acuity substantially underestimates the impact of visual impairment on quality of life compared with binocular visual acuity [Epub ahead of print]. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.056","DOI":"10.1016\/j.ophtha.2020.01.056"},{"key":"4849_CR17","doi-asserted-by":"publisher","unstructured":"Korobelnik J-F, Loewenstein A (2020) Communicating with patients with nAMD and their families during the COVID-19 pandemic [EPub ahead of print]. Graefe\u2019s Arch Clin Exp Ophthalmol:1\u20133. https:\/\/doi.org\/10.1007\/s00417-020-04697-6","DOI":"10.1007\/s00417-020-04697-6"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-04849-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04849-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T23:25:03Z","timestamp":1627169103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-04849-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4849"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04849-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JS Talks: Advisory board; Bayer; Novartis; Allergan; research; Bayer; Novartis; Allergan; Roche; Boehringer IngelheimIMS: Research funding Bayer; Boehringer Ingelheim","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All data were recorded using an electronic medical record (EMR) system (Medisoft Ophthalmology; Medisoft Limited, Leeds, UK), which mandates collection of a standardized data set throughout a patient\u2019s care pathway. The lead clinician and Caldicott Guardian (nominee responsible for data protection) at the hospital gave written approval for anonymized data extraction. Anonymized database analyses of this type do not require ethical permission because they are viewed as audit or service evaluations (see  beforeyou-apply\/determine-whether-your-study-is-research\/). This study was conducted in accordance with the Declaration of Helsinki and the UK\u2019s Data Protection Act.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not available","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}